Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Nerdwallet Inc (NRDS) vs Novavax Inc (NVAX) Price & Performance

Nerdwallet IncTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Nerdwallet Inc vs Novavax Inc — how do they compare? Nerdwallet Inc trades at $9.78 (market cap $625.17M), while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: Novavax Inc is far larger — about 2.1× Nerdwallet Inc's market cap. Which is the better fit depends on your goals.

NRDSNVAX
Market Cap
$625.17M$1.31B
Sector
FinancialsHealth
52-Week High
$15.93$11.19
52-Week Low
$7.58$6.22
Enterprise Value
$539.47M$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Nerdwallet Inc

NerdWallet (NRDS) trades at $9.65, down 1.53% today, but maintains a bullish technical outlook with strong moving average support. The company shows impressive fundamental improvement with revenue growing from $539M in 2022 to $837M in 2025, while turning profitable with net income reaching $49M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, though Q1 and Q4 2025 results beat estimates. The stock trades at attractive valuation multiples with P/E of 10.87 and P/S of 0.81, well below industry averages.

NRDS presents a compelling growth story with strong profitability metrics (18.16% ROE) and analyst consensus leaning bullish (66.7% buy ratings). The primary risk involves execution challenges in transitioning from SEO-dependent referrals to higher-margin transactions. With Wall Street projecting 27.9% upside potential, the stock offers value for investors seeking exposure to financial guidance platforms, though quarterly earnings volatility remains a concern.

Novavax Inc

NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.

The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.

Returns comparison

Trailing returns across standard periods

About Nerdwallet Inc

Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.

Read more on NRDS

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX